PTJ
DAWN

Paul Tudor Jones’s Day One Biopharmaceuticals DAWN Stock Holding History

Paul Tudor Jones’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,000
Closed -$233K – 3741
2025
Q4 		$233K Buy
+25,000
New +$209K ﹤0.01% 3202

Other funds holding DAWN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.75B AUM 102.57% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Paul Tudor Jones's DAWN Position: Q1 2026 in Review

Paul Tudor Jones sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 62,316 shares — an estimated $581K sold.

Paul Tudor Jones first reported a position in DAWN in Q3 2022 and held it in 11 quarters. The position peaked at $768K in Q3 2024. 207 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Paul Tudor Jones reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 62,316 Day One Biopharmaceuticals shares in Q1 2026, an estimated $581K.
  • Paul Tudor Jones first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 11 quarters.
  • Paul Tudor Jones's Day One Biopharmaceuticals position peaked at $768K in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.